Tempest Therapeutics (TPST) Profit After Tax (2012 - 2026)
Tempest Therapeutics (TPST) posted Profit After Tax of -$4.0 million for Q4 2025, down 14.53% sequentially from -$3.5 million in Q3 2025, and up 70.89% YoY from -$2.4 million in Q4 2024.
Tempest Therapeutics (TPST) Profit After Tax (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Profit After Tax for 14 years, with the latest figure at -$4.0 million in Q4 2025.
- Quarterly Profit After Tax rose 70.89% year-over-year to -$4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.3 million (up 37.24% YoY) and the FY2025 annual result came in at -$26.3 million, up 37.24% from the prior year.
- Profit After Tax retreated to -$4.0 million in Q4 2025 per TPST's latest filing, from -$3.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$3.5 million in Q3 2025 and troughed at -$13.8 million in Q4 2024.
- A 5-year average of -$8.1 million and a median of -$7.9 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 84.47% in 2024, then soared 70.89% in 2025.
- Over 5 years, Profit After Tax stood at -$7.7 million in 2021, then slipped by 18.37% to -$9.1 million in 2022, then climbed by 17.74% to -$7.5 million in 2023, then slumped by 84.47% to -$13.8 million in 2024, then jumped by 70.89% to -$4.0 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$4.0 million, -$3.5 million, and -$7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | -5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.24 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | -7.87 Mn |
| Mar 31, 2025 | -10.86 Mn |
| Dec 31, 2024 | -13.81 Mn |
| Sep 30, 2024 | -10.56 Mn |
| Jun 30, 2024 | -9.57 Mn |
| Mar 31, 2024 | -7.90 Mn |
| Dec 31, 2023 | -7.49 Mn |
| Sep 30, 2023 | -6.79 Mn |
| Jun 30, 2023 | -7.58 Mn |
| Mar 31, 2023 | -7.64 Mn |
| Dec 31, 2022 | -9.10 Mn |
| Sep 30, 2022 | -8.95 Mn |
| Jun 30, 2022 | -9.17 Mn |
| Mar 31, 2022 | -8.49 Mn |
| Dec 31, 2021 | -7.69 Mn |
| Sep 30, 2021 | -8.11 Mn |
| Jun 30, 2021 | -7.06 Mn |